FY25 Results Investor Presentation
| Stock | Imricor Medical Systems Inc (IMR.ASX) |
|---|---|
| Release Time | 25 Feb 2026, 7:45 a.m. |
| Price Sensitive | Yes |
FY25 Results Investor Presentation
- CE Mark approval under MDR for 2nd generation ablation catheter and capital equipment
- CE mark approval received for NorthStar - world's only MRI native 3D mapping and guidance system
- Successfully performed first-in-human ischemic VT ablation under real time MRI guidance
Imricor Medical Systems, Inc. (ASX:IMR) announced its FY25 results, highlighting key milestones achieved during the year. The company received CE Mark approval under the Medical Device Regulation (MDR) for its 2nd generation ablation catheter and capital equipment, as well as CE mark approval for its NorthStar - the world's only MRI native 3D mapping and guidance system. Imricor also successfully performed the first-in-human ischemic ventricular tachycardia (VT) ablation under real-time MRI guidance, completed a human factors study involving 20 U.S. hospitals to support FDA approval, and added new clinical trial sites in Europe and the U.S. The company continued to strengthen its balance sheet, raising US$44 million through an institutional placement, and managed its costs effectively with an operating cash outflow of US$19 million in FY25. Despite a temporary revenue impact due to customer sites performing clinical trial cases, Imricor remains focused on driving the adoption of its MRI-guided cardiac ablation technology and expanding its commercial footprint globally.
Imricor expects to generate revenue from its MRI-guided cardiac ablation products, with estimated average selling prices ranging from US$3,500 to US$6,500 per procedure depending on the indication and market. The company is targeting the large global addressable market for cardiac ablation procedures, which is estimated to grow at a 15% CAGR to 2032.
Imricor is well-positioned to capitalize on the growing global cardiac ablation market, with its regulatory approvals, successful clinical trials, and expanding commercial footprint. The company is focused on driving the adoption of its MRI-guided cardiac ablation technology, which offers significant benefits to patients, physicians, and healthcare providers.